January 10, 2022 -- Eikon Therapeutics has closed a $517.8 million series B financing round and completed the recruitment of an experienced team of industry executives to senior leadership positions. Since its founding two years ago, Eikon Therapeutics has raised more than $668 million.
Eikon employs super-resolution microscopy and advanced engineering to invent novel medicines. Elkon aims to permit precise characterization of protein interactions in living cells with exceptional spatial and temporal resolution. This approach requires the integration of tools that support advanced imaging, high-performance computing, molecular and cellular biology, medicinal chemistry, and robotics, the company said.
New investors participating in the financing round include funds and accounts advised by T. Rowe Price Associates, the Canada Pension Plan Investment Board (CPP Investments), EcoR1 Capital, UC Investments, ADIA, StepStone Group, Soros Capital, Schroders Capital, Harel Insurance, General Catalyst, E15 VC, Hartford Healthcare Endowment, and AME Cloud Ventures. The financing also included participation from the company's series A investors, the Column Group, Foresite Capital, Innovation Endeavors, Lux Capital, and Horizons Ventures.
Copyright © 2022 scienceboard.net